Retinoids have a pronounced antiviral effect against several viruses. In this study we aimed to investigate the effect of retinoids on human herpesvirus 8 (HHV-8).
Methods
A panel of retinoic acid compounds were tested for their antiviral activity against HHV-8 in human umbilical vascular endothelial cells (HUVECs) and in a human epithelial cell line. The presence, transcription and antigen expression of HHV-8 in infected cells – in the presence or absence of retinoic acid compounds – were evaluated by PCR, reverse transcriptase PCR and immunofluorescence assays; HHV-8 viral load was determined by real-time quantitative PCR. Angiogenesis induced by HHV-8 was also assessed using Cultrex® basement membrane extract.
Results
The compounds tested specifically inhibited viral promoters, during the early and late phases of infection in both cell systems tested, and resulted in up to 100fold reduction of viral titre and release of progeny virus. The inhibition of viral replication induced by retinoids in endothelial cells, the primary target of HHV-8-driven transformation in Kaposi's Sarcoma, prevented endothelial cells from developing spindle morphology and in vitro tube formation, characteristic changes associated with HHV-8 infection and transformation.
Conclusions
We show that retinoids inhibit HHV-8 replication and identify new retinoid compounds with a strong antiviral effect. Selective retinoids, particularly those with retinoic acid receptor agonist activity, may be good candidates for the development of antiviral drugs.
References
1.
CathomasG.Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus.Herpes2003; 10: 72–77.
2.
RegeziJ.A., MacPhailL.A., DanielsT.E., DeSouzaY.G., GreenspanJ.S., GreenspanD.Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells.Am J Pathol1993; 143: 240–249.
3.
HuangS.K., MartinF.J., JayG., VogelJ., PapahadjopoulosD., FriendD.S.Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene.Am J Pathol1993; 143: 10–14.
4.
RenwickN., HalabyT., WeverlingG.J.Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.AIDS1998; 12: 2481–2488.
5.
FloreO., RafiiS., ElyS., O'LearyJ.J., HyjekE.M., CesarmanE.Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.Nature1998; 394: 588–592.
6.
De ClercqE., NaesensL., De BolleL., ScholsD., ZhangY., NeytsJ.Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.Rev Med Virol2001; 11: 381–395.
7.
MedveczkyM.M., HorvathE., LundT., MedveczkyP.G.In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.AIDS1997; 11: 1327–1332.
8.
SenanayakeS., KellyJ., LloydA., WaliuzzamanZ., GoldsteinD., RawlinsonW.Multicentric Castleman's disease treated with antivirals and immunosuppressants.J Med Virol2003; 71: 399–403.
9.
JamesJ.S.Kaposi's sarcoma: new topical treatment approved.AIDS Treat News1999: 1.
10.
DuvicM., Friedman-KienA.E., LooneyD.J.Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.Arch Dermatol2000; 136: 1461–1469.
11.
WalmsleyS., NorthfeltD.W., MeloskyB., ConantM., Friedman-KienA.E., WagnerB.Treatment of AIDS-related cutaneous Kaposi’ sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.J Acquir Immune Defic Syndr1999; 22: 235–246.
BodsworthN.J., BlochM., BowerM., DonnellD., YocumR.Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma.Am J Clin Dermatol2001; 2: 77–87.
14.
MilesS.A., DezubeB.J., LeeJ.Y.Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.AIDS2002; 16: 421–429.
15.
AboulafiaD.M., NorrisD., HenryD.9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial.Arch Dermatol2003; 139: 178–186.
16.
BernsteinZ.P., Chanan-KhanA., MillerK.C., NorthfeltD.W., Lopez-BeresteinG., GillP.S.A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunode∼ficiency syndrome-associated Kaposi's sarcoma.Cancer2002; 95: 2555–2561.
17.
CorbeilJ., RapaportE., RichmanD.D., LooneyD.J.Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.J Clin Invest1994; 93: 1981–1986.
18.
NagpalS., CaiJ., ZhengT.Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma.Mol Cell Biol1997; 17: 4159–4168.
19.
MajewskiS., MarczakM., SzmurloA., JablonskaS., BollagW.Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids.Cancer Lett1995; 89: 117–124.
20.
LingenM.W., PolveriniP.J., BouckN P.. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells.Lab Invest1996; 74: 476–483.
21.
FerrariN., MoriniM., PfefferU., MinghelliS., NoonanD.M., AlbiniA.Inhibition of Kaposi's sarcoma in vivo by fenretinide.Clin Cancer Res2003; 9: 6020–6029.
22.
DolcettiR., Di LucaD., de LeraA.Natural and synthetic retinoids: structural bases and biological effects of potential clinical relevance for the prevention and treatment of infection-driven tumors.Anti-Infective Agents in Medicinal Chemistry2006; 5: 85–103.
23.
DominguezB., PazosY., de LeraA.R.Stereocontrolled synthesis of 6-s-cis- and 6-s-trans-locked 9Z-retinoids by hydroxyl-accelerated Stille coupling of (Z)-tri-n-butylstannylbut-2-en-1-ol and bicyclic dienyl triflates.J Org Chem2000; 65: 5917–5925.
24.
PazosY., de LeraA.R.Stereoselective synthesis of 9-cis-retinoic acid based on stepwise or convergent suzuki coupling reactions.Tetrahedron Letters1999; 40: 8287–8290.
25.
CaselliE., GalvanM., CassaiE., CarusoA., SighinolfiL., Di LucaD.Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells.Blood2005; 106: 2790–2797.
26.
CarusoA., RotolaA., ComarM.HHV-6 infects human aortic and heart microvascular endothelial cells, increasing their ability to secrete proinflammatory chemokines.J Med Virol2002; 67: 528–533.
27.
CaselliE.F.S., AmiciC., Di LucaD., CarusoA., SantoroM.G.Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NFκB pathway.Blood2007; 109: 2718–2726.
SantoniF., LindnerI., CaselliE., GoltzM., Di LucaD., EhlersB.Molecular interactions between porcine and human gammaherpesviruses: implications for xenografts?Xenotransplantation2006; 13: 308–317.
30.
NeytsJ., De ClercqE.Antiviral drug susceptibility of human herpesvirus 8.Antimicrob Agents Chemother1997; 41: 2754–2756.
31.
ZhuW., BurnetteA., DorjsurenD.Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus.Antimicrob Agents Chemother2005; 49: 4965–4973.
32.
SergerieY., BoivinG.Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR.J Clin Microbiol2003; 41: 3897–3900.
33.
PelicanoL., LiF., SchindlerC., Chelbi-AlixM.K.Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action.Oncogene1997; 15: 2349–2359.
34.
BourgeadeM.F., BesanconF.Induction of 2’,5’-oligoadenylate synthetase by retinoic acid in two transformed human cell lines.Cancer Res1984; 44: 5355–5360.
35.
FaluhelyiZ., RodlerI., CsejteyA., TyringS.K., EmberI.A., AranyI.All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner.Anticancer Res2004; 24: 807–809.
36.
HanleyT.M., KieferH.L., SchnitzlerA.C., MarcelloJ.E., VigliantiG.A.Retinoid-dependent restriction of human immunodeficiency virus type 1 replication in monocytes/macrophages.J Virol2004; 78: 2819–2830.
37.
FontanaJ.A., RishiA.K.Classical and novel retinoids: their targets in cancer therapy.Leukemia2002; 16: 463–472.
38.
KlassC.M., OffermannM.K.Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma.Curr Opin Oncol2005; 17: 447–455.
39.
WhitbyD., HowardM.R., Tenant-FlowersM.Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.Lancet1995; 346: 799–802.
40.
CannonM.J., DollardS.C., BlackJ.B.Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus.AIDS2003; 17: 215–222.
41.
MocroftA., YouleM., GazzardB., MorcinekJ., HalaiR., PhillipsA.N.Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.AIDS1996; 10: 1101–1105.
42.
HongW.K., LippmanS.M., ItriL.M.Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.N Engl J Med1990; 323: 795–801.
43.
LalaD.S., MukherjeeR., SchulmanI.G.Activation of specific RXR heterodimers by an antagonist of RXR homodimers.Nature1996; 383: 450–453.
44.
AgarwalC., ChandraratnaR.A., JohnsonA.T., RorkeE.A., EckertR.L.AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells.J Biol Chem1996; 271: 12209–12212.
45.
SzondyZ., ReichertU., BernardonJ.M.Induction of apoptosis by retinoids and retinoic acid receptor gamma-selective compounds in mouse thymocytes through a novel apoptosis pathway.Mol Pharmacol1997; 51: 972–982.
46.
ZhangL., NadzanA.M., HeymanR.A.Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.J Med Chem1996; 39: 2659–2663.
47.
GermainP., KammererS., PerezE.Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.EMBO Rep2004; 5: 877–882.
48.
IvanovaD., GaudonC., RossinA., BourguetW., GronemeyerH.RAR-RXR selectivity and biological activity of new retinoic acid analogues with heterocyclic or polycyclic aromatic systems.Bioorg Med Chem2002; 10: 2099–2102.
49.
AlvarezR., VegaM.J., KammererS.9-cis-Retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists.Bioorg Med Chem Lett2004; 14: 6117–6122.
50.
Canan KochS.S., DardashtiL.J., HebertJ.J.Identification of the first retinoid X, receptor homodimer antagonist.J Med Chem1996; 39: 3229–3234.
51.
SchulmanI.G., CrombieD., BissonetteR.P.RXR-Specific Agonists and modulators: a new retinoid pharmacology. In Retinoids: the Biochemical and Molecular Basis of Vitamin A and retinoid action. Edited by NauH., BlanerW.S.; Springer-VerlagBerlin, Germany.
52.
Canan KochS.S., DardashtiL.J., CesarioR.M.Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.J Med Chem1999; 42: 742–750.
53.
DawsonM.I., ZhangX.K.Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid.Curr Med Chem2002; 9: 623–637.
54.
MichellysP.Y., D'ArrigoJ., GreseT.A.Design, synthesis and structure-activity relationship of novel RXR-selective modulators.Bioorg Med Chem Lett2004; 14: 1593–1598.
